On March 20, 2026, Iovance Biotherapeutics, Inc. revealed that the Company has given the green light for the issuance of inducement stock options on March 19, 2026, covering a total of 3,400 shares of Iovance’s common stock to a recently hired, non-executive staff member. Iovance, a biotech firm dedicated to pioneering, creating, and providing innovative polyclonal tumor infiltrating lymphocyte (“TIL”) treatments for cancer patients, made this announcement.